Papilocare vaginal gel
Sponsors
Procare Health Iberia S.L., Elpen Pharmaceutical Co. Inc., University of Aarhus
Conditions
Cervical DysplasiaCervical Intraepithelial Neoplasia (CIN)Cervix LesionHPV InfectionHuman Papilloma VirusHuman Papilloma Virus (HPV)Human Papilloma Virus InfectionLesion Cervix
Unknown Phase
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
CompletedNCT04002154
Start: 2015-10-19End: 2019-02-28Updated: 2021-02-16
Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.
CompletedNCT04199260
Start: 2018-05-20End: 2021-02-18Updated: 2021-08-09
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
CompletedNCT04199078
Start: 2019-09-25End: 2024-06-30Updated: 2026-09-02
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
CompletedNCT06399341
Start: 2021-09-01End: 2023-04-30Updated: 2024-05-03
Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.
RecruitingNCT07429071
Start: 2026-06-09End: 2026-12-01Target: 70Updated: 2026-08-03